- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01422954
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Malaria is one of the major infectious diseases in the world with a tremendous impact on the quality of life, significantly contributing to the ongoing poverty in endemic countries. It causes 800.000 deaths per year, the majority of which are children under the age of five. The malaria parasite enters the human body through the skin, by the bite of an infected mosquito. Subsequently, it invades the liver and develops and multiplies inside the hepatocytes. After a week, the hepatocytes burst open and the parasites are released in the blood stream, causing the clinical phase of the disease.
As a unique opportunity to study malaria immunology and efficacy of immunisation strategies, a protocol has been developed in the past to conduct controlled human malaria infections (CHMIs). CHMIs generally involve small groups of malaria-naïve volunteers infected via the bites of P. falciparum infected laboratory-reared Anopheline mosquitoes. Although potentially serious or even lethal, P. falciparum malaria can be radically cured at the earliest stages of blood infection when risks of complications are virtually absent.
The investigators have shown previously that healthy human volunteers can be protected from a malaria mosquito (sporozoite) challenge by immunization with sporozoites (by mosquito bites) under chloroquine prophylaxis (CPS immunization). Interestingly, sterile protection in 100% of the human CPS immunized volunteers was achieved by a relatively miniscule dose, i.e. a total of 45 infectious mosquito bites, strikingly 20-fold more potent than the 1000 bites needed in a model using irradiated mosquitoes. One possible explanation for this efficient induction of protective immunity, is the immune modulating effect of chloroquine. The investigators aim to assess this possible immune modulating effect in CPS immunization by comparing immunization with P. falciparum sporozoites under chloroquine with immunization under mefloquine prophylaxis, which has the same antimalarial effect, but not the immune modulating effects known from chloroquine.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leiden, Netherlands, 2333 ZA
- Leiden University Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 and < 35 years healthy volunteers (males or females)
- Good health based on history and clinical examination
- Negative pregnancy test
- Use of adequate contraception for females
- Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study
- Agreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study
- Willingness to undergo a Pf controlled infection through mosquito bites
- Agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till treatment is finished)
- Reachable (24/7) by mobile phone during the whole study period
- Available to attend all study visits
- Agreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period
- Willingness to undergo HIV, hepatitis B and hepatitis C tests
- Negative urine toxicology screening test at screening visit and the day before challenge
- Willingness to take a prophylactic regime of chloroquine or mefloquine and curative regimen of Malarone®
Exclusion Criteria:
- History of malaria
- Plans to travel to malaria endemic areas during the study period
- Plans to travel outside of the Netherlands during the challenge period
- Previous participation in any malaria vaccine study and/or positive serology for Pf
- Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
- History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
- History of arrhythmias or prolonged QT-interval
- Positive family history in 1st and 2nd degree relatives for cardiac events < 50 years old
- An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
- Clinically significant abnormalities in electrocardiogram (ECG) at screening
- Body Mass Index (BMI) below 20 or above 30 kg/m2
- Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
- Positive HIV, HBV or HCV tests
- Participation in any other clinical study within 30 days prior to the onset of the study
- Enrollment in any other clinical study during the study period
- For women: pregnancy or lactation
- Volunteers unable to give written informed consent
- Volunteers unable to be closely followed for social, geographic or psychological reasons
- History of drug or alcohol abuse interfering with normal social function
- A history of treatment for psychiatric disease or moderate or severe psychological episode in volunteer
- A history of convulsions in volunteer
- Severe depression, anxiety disorder of psychosis in first or second degree family
- Contra-indications to Malarone®, chloroquine or mefloquine including hypersensitivity or treatment taken by the volunteer that interferes with Malarone®, chloroquine or mefloquine
- The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids and oral anti-histaminic are allowed) and during the study period
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia
- Co-workers or trainees of the departments of Medical Microbiology, Parasitology, or Internal Medicine of the Leiden University medical Centre
- A history of sickle cell anemia, sickle cell trait, thalassemia, thalassemia trait or G6PD deficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Chloroquine immunisation
This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
|
Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks.
On day 0, day 3, day 7 and day 10, this group will receive a placebo.
Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites.
Group 3 will receive an equal number of uninfected mosquito-bites.
Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Other Names:
|
EXPERIMENTAL: Mefloquine immunisation
This group will receive mefloquine prophylaxis and infected mosquito-bites.
|
Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites.
Group 3 will receive an equal number of uninfected mosquito-bites.
Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Other Names:
Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
|
PLACEBO_COMPARATOR: Mefloquine control
This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
|
Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites.
Group 3 will receive an equal number of uninfected mosquito-bites.
Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Other Names:
Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of prepatent period after challenge infection as measured by microscopy
Time Frame: 21 days after challenge (day 239 of the study)
|
21 days after challenge (day 239 of the study)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Development of parasitemia as measured by PCR
Time Frame: 21 days after challenge (day 239 of study)
|
21 days after challenge (day 239 of study)
|
Frequency of signs or symptoms in study groups
Time Frame: Day 0 - day 358 of study
|
Day 0 - day 358 of study
|
Cellular immune responses between study groups
Time Frame: Day 0 -day 358 of study
|
Day 0 -day 358 of study
|
Humoral immune responses between study groups
Time Frame: Day 0 - 358
|
Day 0 - 358
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antirheumatic Agents
- Antimetabolites
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Chloroquine
- Proguanil
- Atovaquone, proguanil drug combination
- Mefloquine
Other Study ID Numbers
- ZonMw2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Chloroquine prophylaxis
-
University of Maryland, BaltimoreNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Radboud University Medical CenterCompletedPlasmodium Falciparum MalariaNetherlands
-
Radboud University Medical CenterCompletedPlasmodium Falciparum MalariaNetherlands
-
University of MalayaUnknownOrthodontic Appliance Complication
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedGraft Versus Host Disease | Ophthalmologic ComplicationsUnited States
-
Ministry of Health and Medical Services, Solomon...World Health OrganizationTerminatedMalaria | Malaria in PregnancySolomon Islands
-
Institut Pasteur du CambodgeSanofi Pasteur, a Sanofi CompanyCompletedRabies Post-exposure ProphylaxisCambodia
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownLung Transplant; Complications
-
Margaret RagniWithdrawn
-
Dinka DugassaEthiopian Public Health InstituteCompletedMalaria | Efficacy | Vivax Malaria | ChloroquineEthiopia